Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 11 to 20 of 1447 total matches.
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
Letter ® Vol. 66 (1700) April 15, 2024
58
Table 3. Some Topical Products for Seborrheic Dermatitis1 ...
The FDA has approved a 0.3% foam formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of seborrheic
dermatitis in patients ≥9 years old. Roflumilast is
the first PDE4 inhibitor to be approved in the US for
this indication. It is also available in a 0.3% cream
formulation (Zoryve) for treatment of plaque psoriasis
and in an oral formulation (Daliresp, and generics) for
treatment of chronic obstructive pulmonary disease.
A 0.15% cream formulation for treatment of atopic
dermatitis in patients ≥6 years old will be reviewed...
Med Lett Drugs Ther. 2024 Apr 15;66(1700):57-9 doi:10.58347/tml.2024.1700a | Show Introduction Hide Introduction
Cabtreo: A Three-Drug Gel for Acne
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
(almost clear).
The Medical Letter ® Vol. 66 (1700) April 15, 2024
60
Table 2. Some Topical Products ...
The FDA has approved Cabtreo (Bausch Health), a gel
containing the retinoid adapalene, the oxidizing agent
benzoyl peroxide, and the antibiotic clindamycin, for
treatment of acne vulgaris in patients ≥12 years old.
Cabtreo is the first three-drug topical formulation to
become available in the US for treatment of acne.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):59-60 doi:10.58347/tml.2024.1700b | Show Introduction Hide Introduction
Zilucoplan (Zilbrysq) for Myasthenia Gravis
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
of serious infections.
The Medical Letter ® Vol. 66 (1700) April 15, 2024
61
human dose was associated ...
The FDA has approved the complement C5
inhibitor zilucoplan (Zilbrysq – UCB) for once-daily
subcutaneous treatment of generalized myasthenia
gravis (gMG) in adults who are anti-acetylcholine
receptor (AChR) antibody-positive. Zilucoplan is
the first complement inhibitor to be approved for
treatment of myasthenia gravis that can be self-administered.
Two IV complement inhibitors,
eculizumab (Soliris) and ravulizumab (Ultomiris),
were approved earlier.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):60-2 doi:10.58347/tml.2024.1700c | Show Introduction Hide Introduction
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
creatinine
clearance, have been reported with long-term use of
The Medical Letter ® Vol. 66 (1699) April 1 ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
Omalizumab (Xolair) for Food Allergy
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
. A constellation
of symptoms similar to those seen in patients determined.
The Medical Letter ® Vol. 66 (1699 ...
Omalizumab (Xolair – Genentech), a recombinant
anti-IgE monoclonal antibody FDA-approved for
treatment of allergic asthma, chronic rhinosinusitis
with nasal polyps, and chronic urticaria, has now
also been approved for use in conjunction with food
allergen avoidance to reduce IgE-mediated food
allergic reactions caused by accidental exposure in
patients ≥1 year old. Omalizumab is the first drug to
be approved in the US to reduce allergic reactions to
more than one food. Palforzia, an oral peanut allergen
powder, was approved in 2020 to mitigate allergic
reactions caused by...
Med Lett Drugs Ther. 2024 Apr 1;66(1699):54-6 doi:10.58347/tml.2024.1699b | Show Introduction Hide Introduction
Addendum: Bupropion Safety in Pregnancy
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
: Lippincott Williams &
Wilkins, 2021.
The Medical Letter ® Vol. 66 (1699) April 1, 2024 bupropion drug ...
Our December 11, 2023 article on Drugs for Depression included a single sentence on the safety of bupropion use during
pregnancy: "The safety of bupropion during pregnancy has
not been established; data from a bupropion pregnancy registry
suggested a possible increase in cardiac malformations."
A reader asked us to provide more information.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):56 doi:10.58347/tml.2024.1699c | Show Introduction Hide Introduction
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
.3,4
The Medical Letter ® Vol. 66 (1698) March 18, 2024
42
similar with albuterol 180 mcg/budesonide ...
The FDA has approved Airsupra (AstraZeneca), a
metered-dose inhaler containing the short-acting
beta2-agonist (SABA) albuterol and the inhaled
corticosteroid (ICS) budesonide, for use as needed for
treatment or prevention of bronchoconstriction and to
reduce the risk of exacerbations in patients ≥18 years
old with asthma. Airsupra is the first combination of
a SABA and an ICS to become available in the US. It is
not approved for use as maintenance therapy.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):41-3 doi:10.58347/tml.2024.1698a | Show Introduction Hide Introduction
Penbraya: A Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
. All rights
reserved. ©2024. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter ® Vol. 66 ...
The FDA has licensed Penbraya (Pfizer), a pentavalent
polysaccharide conjugate meningococcal
vaccine, for prevention of invasive meningococcal
disease caused by Neisseria meningitidis
serogroups A, B, C, W, or Y (MenABCWY) in persons
10-25 years old. Penbraya is the only meningococcal
vaccine that contains all five of these serogroups.
Two quadrivalent polysaccharide conjugate
meningococcal vaccines containing serogroups A,
C, W, and Y (MenACWY; Menveo, MenQuadfi) and
two meningococcal serogroup B vaccines (MenB;
Bexsero, Trumenba) are available in the US (see
Table...
Med Lett Drugs Ther. 2024 Mar 18;66(1698):43-5 doi:10.58347/tml.2024.1698b | Show Introduction Hide Introduction
Mirikizumab (Omvoh) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
with ulcerative colitis)
The Medical Letter ® Vol. 66 (1698) March 18, 2024
47
In LUCENT II, 544 patients who ...
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first selective
IL-23 antagonist to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment of UC in 2019. The IL-23
antagonist risankizumab (Skyrizi) is approved for
treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7 doi:10.58347/tml.2024.1698c | Show Introduction Hide Introduction
In Brief: A New OTC Naloxone Nasal Spray (RiVive)
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
.
9. Cost at www.walgreens.com. Accessed February 29, 2024.
The Medical Letter ® Vol. 66 (1698) March ...
The FDA has approved RiVive (Harm Reduction
Therapeutics), a 3-mg naloxone nasal spray, as
an over-the-counter (OTC) product for emergency
treatment of opioid overdose. Two 4-mg naloxone
nasal spray formulations, Narcan and one of its
generics, were approved for OTC sale in 2023.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):47-8 doi:10.58347/tml.2024.1698d | Show Introduction Hide Introduction